3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
84
Breast Neoplasms
34
Colorectal Neoplasms
26
Lung Neoplasms
23
Rectal Neoplasms
22
Neoplasms
21
Esophageal Squamous Cell Carcinoma
20
Neoplasm Metastasis
19
Esophageal Neoplasms
19
Head and Neck Neoplasms
17
Stomach Neoplasms
15
Pancreatic Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
14
Triple Negative Breast Neoplasms
12
Small Cell Lung Carcinoma
12
Ovarian Neoplasms
11
Nasopharyngeal Carcinoma
10
Carcinoma, Squamous Cell
10
Recurrence
9
Leukemia, Myeloid, Acute
9
Colonic Neoplasms
9
Uterine Cervical Neoplasms
8
Prostatic Neoplasms
7
Lymphoma, Large B-Cell, Diffuse
7
Lymphoma
7
Glioblastoma
7
Sarcoma
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Melanoma
6
Lymphoma, Non-Hodgkin
6
Interventions
apatinib
3
vistusertib
2
olaparib
2
camrelizumab
2
atezolizumab
2
Ipilimumab
2
Everolimus
2
trametinib
1
toripalimab
1
tilsotolimod
1
tazemetostat
1
tazarotene
1
spartalizumab
1
seviteronel
1
sargramostim
1
sacituzumab govitecan
1
rucaparib
1
roniciclib
1
romiplostim
1
pyrotinib
1
phosphorylethanolamine
1
pemigatinib
1
pembrolizumab
1
pazopanib
1
palbociclib
1
niraparib
1
magrolimab
1
lenvatinib
1
irinotecan sucrosofate
1
famitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Solid Tumor
×
Drug Therapy
×
Clear all
NCT05898451
2023-06-12
R-2
Refnot-Pharm Ltd
Phase 2
Completed
55 enrolled